Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shandong Univ. NLRP3 inflammasome compound 5b
- Development stage
- Unknown
- Lead developer
- Shandong University
01
Overview
Shandong Univ. NLRP3 inflammasome compound 5b: sourced facts only. name: "The most potent two hits 7a and 5b showed inhibition on the NLRP3 inflammasome with the IC50 of 1.83 ± 0.28 µM and 0.91 ± 0.06 µM, respectively." [PMID:35914391]; target: "The most potent two hits 7a and 5b showed inhibition on the NLRP3 inflammasome with the IC50 of 1.83 ± 0.28 µM and 0.91 ± 0.06 µM, respectively." [PMID:35914391]; developer: "Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China." [PMID:35914391]
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Shandong Univ. NLRP3 inflammasome compound 5b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Univ. NLRP3 inflammasome compound 5b.